A Relationship of the cardiac biomarkers with COVID-19: A review
DOI:
https://doi.org/10.54153/sjpas.2020.v2i3.54Abstract
This review was designed to find out the effect of biomarkers used as predictive signs for the diagnosis of cardiac injury on COVID-19 patients and the probability of death. The current literature has been reviewed and some results considered. A systematic literary research has been conducted in Google Scholar, Web of Science and Pubmed for research starting from the date the disease appeared In December 2019 until the beginning of April 2020, the references used research phrases containing COVID-19 and its relationship to predictive indicators of cardiac injury. The results of the citations showed 8 researches related to this topic that used cardiac biomarkers that are high sensitive Cardiac troponin (Hs-cTn) and Natriuretic peptides (NP), creatine kinase type MB (CK-MB) and high sensitive C-reactive protein(Hs-CRP) and lactate dehydrogenase(LDH) with COVID-19 patients. This review concluded that there was a significant increase in cardiac biomarkers in those with COVID-19 who had a medical history of cardiac injury who were more likely to die.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Samarra Journal of Pure and Applied Science

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright Notice
Authors retain copyright and grant the SJPAS journal right of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in Samarra Journal of Pure and Applied Science.
The Samarra Journal of Pure and Applied Science permits and encourages authors to archive Pre-print and Post-print items submitted to the journal on personal websites or institutional repositories per the author's choice while providing bibliographic details that credit their submission, and publication in this journal. This includes the archiving of a submitted version, an accepted version, or a published version without any Risks.



